|
Name |
Methyl 13-methyltetradecanoate
|
| Molecular Formula | C16H32O2 | |
| IUPAC Name* |
methyl 13-methyltetradecanoate
|
|
| SMILES |
CC(C)CCCCCCCCCCCC(=O)OC
|
|
| InChI |
InChI=1S/C16H32O2/c1-15(2)13-11-9-7-5-4-6-8-10-12-14-16(17)18-3/h15H,4-14H2,1-3H3
|
|
| InChIKey |
OGGUSDOXMVVCIX-UHFFFAOYSA-N
|
|
| Synonyms |
Methyl 13-methyltetradecanoate; 5129-59-9; 13-Methyltetradecanoic acid methyl ester; Methyl 13-methylmyristate; ACIDRED106; Tetradecanoic acid, 13-methyl-, methyl ester; SCHEMBL2345504; DTXSID80408101; ZINC4557095; FT-0702482; Methyl 13-methylmyristate, >=98% (capillary GC); Q63398303; 7DF3C627-D518-4FB9-A6FA-62906776919B
|
|
| CAS | 5129-59-9 | |
| PubChem CID | 5077204 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 256.42 | ALogp: | 7.1 |
| HBD: | 0 | HBA: | 2 |
| Rotatable Bonds: | 13 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
| Heavy Atoms: | 18 | QED Weighted: | 0.344 |
| Caco-2 Permeability: | -4.606 | MDCK Permeability: | 0.00001630 |
| Pgp-inhibitor: | 0.151 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.964 |
| 30% Bioavailability (F30%): | 0.971 |
| Blood-Brain-Barrier Penetration (BBB): | 0.478 | Plasma Protein Binding (PPB): | 97.09% |
| Volume Distribution (VD): | 1.215 | Fu: | 1.94% |
| CYP1A2-inhibitor: | 0.634 | CYP1A2-substrate: | 0.232 |
| CYP2C19-inhibitor: | 0.556 | CYP2C19-substrate: | 0.302 |
| CYP2C9-inhibitor: | 0.431 | CYP2C9-substrate: | 0.961 |
| CYP2D6-inhibitor: | 0.036 | CYP2D6-substrate: | 0.043 |
| CYP3A4-inhibitor: | 0.365 | CYP3A4-substrate: | 0.107 |
| Clearance (CL): | 5.931 | Half-life (T1/2): | 0.321 |
| hERG Blockers: | 0.097 | Human Hepatotoxicity (H-HT): | 0.036 |
| Drug-inuced Liver Injury (DILI): | 0.347 | AMES Toxicity: | 0.005 |
| Rat Oral Acute Toxicity: | 0.028 | Maximum Recommended Daily Dose: | 0.015 |
| Skin Sensitization: | 0.948 | Carcinogencity: | 0.078 |
| Eye Corrosion: | 0.945 | Eye Irritation: | 0.966 |
| Respiratory Toxicity: | 0.869 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000548 | ![]() |
0.943 | D05ATI | ![]() |
0.448 | ||
| ENC001160 | ![]() |
0.893 | D07ILQ | ![]() |
0.429 | ||
| ENC000848 | ![]() |
0.847 | D0G2KD | ![]() |
0.418 | ||
| ENC001274 | ![]() |
0.820 | D0P1RL | ![]() |
0.407 | ||
| ENC000549 | ![]() |
0.786 | D0Z5SM | ![]() |
0.405 | ||
| ENC001181 | ![]() |
0.769 | D0O1PH | ![]() |
0.381 | ||
| ENC001142 | ![]() |
0.767 | D05QNO | ![]() |
0.380 | ||
| ENC000916 | ![]() |
0.764 | D0T9TJ | ![]() |
0.370 | ||
| ENC000495 | ![]() |
0.759 | D0Z5BC | ![]() |
0.365 | ||
| ENC000604 | ![]() |
0.719 | D00MLW | ![]() |
0.354 | ||